This pharmaceutical-development technology company continues to demonstrate that its testing platform has real potential.
Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
The "Subject B" exam, which consists of 20 questions to be solved in 100 minutes, significantly impacts whether you pass or ...
点击上方“Deephub Imba”,关注公众号,好文章不错过 !数据分块可以把超大文档拆成 AI ...
A Beginner's Guide to the Sliding Window Algorithm with JavaScript Learn the basics of the Sliding Window algorithm in ...
The new closed-loop discovery system outperformed AI systems from OpenAI and Anthropic on a public biology benchmark, advancing scientific discovery through autonomous experimentation at scale. NEW ...
Edex Live on MSN
GATE 2027 DA preparation: Three-year question paper analysis reveals high-weightage topics and study priorities
Candidates preparing for the GATE 2027 Data Science and Artificial Intelligence (DA) paper can use the previous three ...
Box ManipulationIn the history of artificial intelligence and machine learning, the determination of internal parameters ...
System logs generated by globally distributed microservices often hide subtle degradations (like memory thrashing or systemic ...
New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results